2. Search Result
Search Result
Results for "

choroidal neovascularization

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

1

Peptides

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-118530
    Bucillamine

    SA96; Thiobutarit

    		 VEGFR Cardiovascular Disease Inflammation/Immunology
    Bucillamine (SA96) is an orally active and potent sulfhydryl donor and antioxidant. Bucillamine is also an antirheumatic agent with antiangiogenic properties. Bucillamine can protect against Ischemia/reperfusion (I/R) injury in high-risk organ transplants. Bucillamine inhibits the production of VEGF. Bucillamine can be used for the research of choroidal neovascularization (CNV) and rheumatoid arthritis (RA) .
    Bucillamine
  • HY-15492
    AG-13958
    1 Publications Verification

    AG-013958

    		 VEGFR Cardiovascular Disease
    AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD) .
    AG-13958
  • HY-132126
    SPHINX

    		SRPK Others
    SPHINX is a selective SRPK1 inhibitor with an IC50 value of 0.58 μM. SPHINX effectively reduces Choroidal Neovascularization (CNV) in vivo. SPHINX can be used for the research of (age-related macular degenaration) AMD .
    SPHINX
  • HY-P3369
    Gersizangitide

    AXT-107

    		 VEGFR Tie Cardiovascular Disease Metabolic Disease
    Gersizangitide (AXT107) is an angiogenic inhibitor peptide containing 20 amino acids.Gersizangitide is a VEGF-A and VEGF-C inhibitor and a Tie2 activator. Gersizangitide is a collagen IV-derived peptide that blocks VEGF receptor signaling and suppresses vascular leakage in ischemic retinopathy and choroidal neovascularization .
    Gersizangitide
  • HY-118530R
    Bucillamine (Standard)

    		VEGFR Cardiovascular Disease Inflammation/Immunology
    Bucillamine (Standard) is the analytical standard of Bucillamine. This product is intended for research and analytical applications. Bucillamine (SA96) is an orally active and potent sulfhydryl donor and antioxidant. Bucillamine is also an antirheumatic agent with antiangiogenic properties. Bucillamine can protect against Ischemia/reperfusion (I/R) injury in high-risk organ transplants. Bucillamine inhibits the production of VEGF. Bucillamine can be used for the research of choroidal neovascularization (CNV) and rheumatoid arthritis (RA) .
    Bucillamine (Standard)
  • HY-15492A
    AG-13958 (mono(hydrochloride))

    AG-013958 monohydrochloride

    		 VEGFR Cardiovascular Disease
    AG-13958 monohydrochloride, a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD) .
    AG-13958 (mono(hydrochloride))
  • HY-153484A
    Bevasiranib sodium

    		VEGFR Small Interfering RNA (siRNA) Others
    Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
    Bevasiranib sodium
  • HY-153484
    Bevasiranib

    		VEGFR Small Interfering RNA (siRNA) Others
    Bevasiranib is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
    Bevasiranib
  • HY-116312
    8-CPT-2'-O-Me-cAMP

    		Ras Cardiovascular Disease
    8-CPT-2'-O-Me-cAMP is a Rap1 activator. 8-CPT-2'-O-Me-cAMP enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration .
    8-CPT-2'-O-Me-cAMP

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: